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Abstract
Background: Recent studies have suggested that cancer cells contain subpopulations that can initiate tumor growth,
self-renew, and maintain tumor cell growth. However, for esophageal cancer cells, the relationship between STAT3,
microRNAs and cancer stem cells remains unclear.
Methods: Serum-free culture was used to enrich esophageal cancer stem-like cells (ECSLC). Flow cytometry
determined the proportion of ECSLC. qPCR were performed to examine expression level of stemness factors,
mesenchymal markers, ATP-binding cassette (ABC) transporters, STAT3, miR-181b, CYLD. Western blot were
performed to analyze the expression of STAT3, p-STAT3 and CYLD (cylindromatosis). BALB/c mice xenograft
studies were conducted to evaluate the tumorigenicity of enriched ECSLC. Sphere formation assay and colony
formation assays were employed to analyze the relationship between STAT3 and miR-181b. Luciferase assays
were used to evaluate activity which CYLD is a target of miR-181b.
Results: Sphere formation cells (SFCs) with properties of ECSLC were enriched. Enriched SFCs in serum-free
suspension culture exhibited cancer stem-like cell properties and increased single-positive CD44 + CD24-, stemness
factor, mesenchymal marker expression ABC transporters and tumorigenicity in vivo compared with the parental cells.
Additionally, we found that reciprocal activation between STAT3 and miR-181b regulated SFCs proliferation. Moreover,
STAT3 directly activated miR-181b transcription in SFCs and miR-181b then potentiated p-STAT3 activity. Luciferase
assays indicated that CYLD was a direct and functional target of miR-181b.
Conclusion: The mutual regulation between STAT3 and miR-181b in SFCs was required for proliferation and apoptosis
resistance. STAT3 and miR-181b control each other’s expression in a positive feedback loop that regulates SFCs via
CYLD pathway. These findings maybe is helpful for targeting ECSLC and providing approach for esophageal cancer
treatments.
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Background
Esophageal cancer includes two major pathological types:
esophageal adenocarcinomas and esophageal squamous
cell carcinoma (ESCC). ESCC is an aggressive malignant
cancer and is the sixth most common cancer type [1]. The
5-year survival rate of esophageal cancer patients is only
10 % [2]. ESCC often occurs in developing countries, in-
cluding China and other countries in Asia [3, 4]. Although
researchers have made much progress in the diagnosis
and treatment of ESCC, the mortality rate has not been
significantly reduced because of late diagnosis, metastasis,
and a lack of understanding of the cellular and molecular
mechanisms underlying the initiation and progression of
ESCC [5].
Cancer stem cells (CSCs) or tumor-initiating cells are
small subpopulations of cancer cells originally identified
in leukemia cells [6, 7]. CSCs have been isolated and
identified in many solid tumors, including prostate,
brain, colorectal, pancreatic, and breast cancers [8]. This
fraction of cells exhibits critical properties, such as self-
renewal, which maintains the proliferation and growth
of tumors [8, 9]. CSCs can be isolated from solid tumors
using three distinct methods based on the CSC properties
[10–12]. First, CSCs can be isolated by flow cytometry
using CSC-specific cell surface markers such as CD44 or
CD133 [13, 14]. For example, the CSCs of gliomas are iso-
lated by cell sorting with CD133+ cells [13], although
CD133 was first identified on hematopoietic stem cells
[15]. Second, the side populations display properties of
CSCs and the capacity for intracellular Hoechst 33342 ex-
clusion in vitro [16, 17]. ABCG2, an ATPase transporter
protein, is closely correlated with the side population
phenotype [17]. However, ABCG2+ and ABCG2—cancer
cells are similarly tumorigenic [18]. Third, the sphere for-
mation of CSCs is enriched in defined serum-free medium
containing growth factors from solid tumors, which main-
tain the CSCs in an undifferentiated state [19–22].
CSCs are regulated by many factors, including cyto-
kines, chemokines, the microenvironment, and stemness
factors [9, 23]. Signal transducer and activators of tran-
scription 3 (STAT3), a transcription factor that is constitu-
tively activated in several cancer types and is correlated
with tumorigenesis, is considered to be an oncogene [24].
Previous studies have indicated that STAT3 is critical in
liver cancer stem cells and glioma stem cells [25, 26]. In
addition, over-activation of STAT3 has been correlated
with tumor invasion and metastasis [27]. However, it is
not clear whether STAT3 regulates esophageal cancer stem
cells. The molecular mechanism underlying the mainten-
ance of self-renewal in esophageal cancer stem cells has yet
not been determined.
microRNAs (miRNAs) are small non-coding RNAs
that suppress gene expression at the post-transcriptional
and translational levels by degrading target mRNA or
blocking mRNA translation [28]. As endogenous regu-
lators of gene expression, miRNAs play an important
role in diverse biological processes, including embryonic
stem cell development, stemness maintenance of stem cells,
proliferation, and apoptosis of cancer cells. Previous studies
demonstrated that abnormal expression or functional dys-
regulation of miRNAs is involved in various human cancers
and that miRNAs can function as tumor suppressors or on-
cogenes [29]. Recently, miRNAs have been implicated in
the promotion or suppression of stemness maintenance of
cancer stem cells [30, 31]. Recent studies have demon-
strated that miR-181b plays an important role in regulating
cellular growth, invasion, and apoptosis in different cancers,
including gastric adenocarcinomas, chronic lymphocytic
leukemia, ovarian cancer, and cervical cancer [32, 33]. Add-
itionally, miR-181b was expressed more significantly in
papillary thyroid carcinoma than in counterpart normal tis-
sue [34, 35]. In addition, STAT3 activation of miR-181b is
important for cellular transformation [36]. However, the
regulatory relationship in esophageal cancer stem-like cells
between STAT3 and miR-181b remains unclear.
In this present study, we enriched SFCs and investigated
the function and mutual regulation mechanism of STAT3
and miR-181b in esophageal cancer stem-like cells. STAT3
trans-activates the transcription of miR-181b, whereas
miR-181b positively regulates p-STAT3. Reciprocal regula-
tion between STAT3 and miR-181b is required for prolif-
eration and anti-apoptosis. We further demonstrated that
CYLD is a direct and functional target of miR-181b in
SFCs. Finally, in clinical human ESCC there is a positive
relationship between STAT3 and miR-181b and miR-181b
is inversely association with CYLD.
Results
Isolation and identification of sphere formation cells (SFCs)
According to previous studies [19, 21, 37], esophageal
cancer cell lines Eca109 and Eca9706 were cultured in
serum-free defined medium (SFDM) in ultra-low adher-
ent dishes during cell passaging. Under these conditions,
cancer cells formed tumor spheres after 3–5 days (Fig. 1a).
Eca109 formed bigger size of tumor spheres and more
tumor spheres than Eca9706 (Fig. 1a). Tumor spheres
were trypsinized and cultured in SFDM again for approxi-
mately five passages. Flow cytometry analysis demon-
strated that enriched SFCs from Eca109 mainly expressed
CD44 + CD24-, which was consistent with the results
of previous studies [38]. The proportion of CD44 +
CD24- of SFCs from Eca109 cells was 6.5 %. However,
the CD44 + CD24- expression level from Eca9706 cells
between parental and sphere cells was not significantly
different (Fig. 1b).
To investigate the cancer stem cell characteristics of
SFCs, stemness factor expression was analyzed. We first
compared the expression levels of Nanog, Oct4, Sox2,
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and Bmi1 between parental cells and SFCs from Eca109
cells. qPCR analysis demonstrated that the expression
levels of these stemness markers were clearly increased
(Fig. 1c). However, an increase in stemness factor ex-
pression was not observed in both cells types from
Eca9706 (Fig. 1d). Stem cell induction, metastasis, and
dedifferentiation have been correlated with the epithelial-
to-mesenchymal transition in different tumor cells [39].
To evaluate whether the transition to mesenchymal traits
was coupled by increased stemness transcription factor ex-
pression, we quantified the expression of mesenchymal
markers. Mesenchymal markers including Snail, Slug, N-
cadherin, ZEB1, and ZEB2 were increased significantly
(Fig. 1e). However, increased mesenchymal markers in
SFCs from Eca9706 were not observed (Fig. 1f). Based on
the above studies and to better understand the properties
Fig. 1 Identification of esophageal cancer stem cell-like cell sphere formation with stemness-related features in serum-free DMEM/F12 medium
(SFDM). a Eca109 and Eca9706 cells were cultured in SFDM, leading to tumor sphere formation. Tumor sphere formation was propagated by
enzymatic dissociation. Cells cultured in regular medium did not form tumor spheres. b Flow cytometry analysis of CD44 and CD24 expressed in
Eca109 and Eca9706 parental cells and their tumor spheres. c, d Stemness factor expression conditions in Eca109 and Eca9706 parental cells and
their tumor spheres quantified by qPCR analysis. e, f qPCR analysis of mesenchymal trait markers expressed in Eca109 and Eca9706 parental cells
and their tumor spheres. Error bars represent mean ± SD
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of esophageal cancer stem cell-like cells, we chose the
Eca109 cell line to perform subsequent experiments.
SFCs exhibited proliferation and tumorigenicity
characteristics of cancer stem cells in vivo
To assess the clonogenic potential of SFCs, colony forma-
tion assays were performed in soft agar. The number of
SFC colonies formed was greater than that of the parental
cells, suggesting that the colony formation capacity of
SFCs is stronger than that of the parental cells (Fig. 2a).
To test the tumorigenic potential of SFCs in a xenograft
mice model, we subcutaneously injected 5 × 105 SFCs and
parental cells into Balb/c mice. Both groups formed solid
tumors. SFCs formed tumors in 6/6 mice. However, injec-
tion of parental cells resulted in tumor formation in 5/6
mice. Tumors of SFC xenografts were three-fold larger
and more vascular than in the parental xenografts (Fig. 2b).
The tumor weights formed by SFCs and parental cells
were 0.15 g and 0.05 g, respectively (Fig. 2b). Next, we
quantified and compared the mRNA expression level from
the harvested tumors in both groups. qPCR analysis dem-
onstrated that CD44 expression of SFC tumors were more
significantly than that of the parental cells. However,
CD24 expression in both groups was not significantly dif-
ferent (Fig. 2c). In addition, the mRNA expression of
multi-drug resistance protein 1 (MRP1) and ABC trans-
porter super-family ABCB1 and ABCG2 were increased
by 2–3.5-fold in SFC xenograft tumors compared with
that in parental cells forming tumors (Fig. 2d). These data
suggest that SFCs have properties of cancer stem cells.
Fig. 2 Analysis of proliferation capacity and tumorigenicity in vivo. a Colony formation assay detection of Eca109 parental cells and tumor sphere
cells. Colonies were counted following 0.5 % crystal violet staining. Triplicate independent experiments were performed. Scale bar = 10 mm.
b Animal experiments for detection of tumorigenicity of Eca109 cells and tumor sphere cells. Subcutaneous tumors formed by Eca109
parental cells and tumor sphere cells. c qPCR analysis of CD44 and CD24 in mouse tumor formation derived from Eca109 parental cells and
SFCs. d mRNA expression of ABCB1, ABCG2, and MRP1 in mice tumors derived from Eca109 parental cells and SFCs. SFCs, sphere formation
cells. Error bars represent mean ± SD
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STAT3 increased sphere formation through miR-181b
pathway
STAT3 is activated constitutively in many types of can-
cer cells and plays a critical role in proliferation, survival,
metastasis, and angiogenesis, making it an attractive
therapeutic target [40–43]. Western blot analysis dem-
onstrated that the p-STAT3 expression level in SFCs was
higher than that in Eca109 parental cells (Fig. 3a). To
investigate the role of STAT3 in SFCs, we performed
colony formation experiments in soft agar. We first
measured the efficiency of the small interfering RNA
(siRNA) against STAT3 (Additional file 1: Figure. S1).
The number of STAT3-depleted SFC colonies was sig-
nificantly lower than by negative control (NC) cells
(Fig. 3b and c). In contrast, STAT3-overexpressed in SFCs
formed more colonies than did the NC (Fig. 3b and c).
These results demonstrate that STAT3 plays a critical role
in proliferation and colony formation.
miR-181b modulates drug resistance in gastric and
lung cancer cells and promotes tumorigenicity in hepa-
tocellular carcinoma [44, 45]. However, the relationship
between STAT3 and miR-181b has not been investigated
in SFCs. Our studies demonstrated STAT3 depletion re-
duced the expression level of miR-181b in SFCs (Fig. 3d).
Consistently, the expression level of miR-181b was also
decreased after the addition of JSI-124, which is a
pharmacological inhibitor of STAT3. In contrast, overex-
pression of STAT3 strongly enhanced the expression
level of miR-181b (Fig. 3d). Moreover, activated STAT3
by IL-6 treatment in SFCs resulted in upregulation of
this miRNA (Fig. 3e). These results demonstrate that
STAT3 trans-activates the transcription of miR-181b. After
Fig. 3 STAT3 trans-activates miR-181b transcription. a Western blot analysis of p-STAT3 and STAT3 in Eca109 parental cells and tumor sphere cells.
b, c Colony formation assays analysis of tumor sphere cells with or without STAT3. Colonies were counted following 0.5 % crystal violet staining.
Triplicate independent experiments were performed. Scale bar = 10 mm. d qPCR analysis of miR-181b expression in SFCs treated with JSI-124 and
with or without STAT3. e qPCR analysis of miR-181b expression levels in SFCs treated with IL-6. f Bioinformatics analysis of predicted binding sites
for STAT3 at the promoter of miR-181b. Schematic representation of the 1650-bp regulatory region upstream of the human miR-181b-stem-loop.
The E-box motifs were predicted at-1650 bp relative to the transcription start site of the human miR-181b stem-loop. g Luciferase assays for promoter
activity. SFCs were dissociated with trypsin and cotransfected with different promoter constructs (wild-type or mutant) and vector expressing STAT3.
h qPCR analysis for expression levels of mature miR-181b, pri-miR-181b in SFCs treated with vector expressing STAT3. β-Actin and U6 snRNA served as
internal controls. SFCs, sphere formation cells. Error bars represent mean ± SD
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determining the molecular mechanism by which STAT3
promotes the expression of miR-181b, we performed a lu-
ciferase reporter assay.
Through bioinformatics analysis using rVista 2.0, we
identified a conserved E-box motif (CANNTG) at 1650 bp
relative to the transcription start site (+1) of the human
miR-181b stem-loop (Fig. 3f). To determine whether
STAT3 influences miR-181 expression, we constructed a
2-kb fragment upstream of the human miR-181b stem-
loop and inserted the fragment into the luciferase reporter
plasmid pGL4.11. This plasmid and the vector expressing
STAT3 were cotransfected into SFCs. We observed a
greater increase in luciferase activity by STAT3 compared
with the empty vector (Fig. 3g). In addition, when the
E-box sequence was mutated, luciferase activity was ab-
rogated (Fig. 3g), indicating that the E-box sequence is
necessary for STAT3 regulation of miR-181b and that
STAT3 binds to the promoter of miR181b. Concordantly,
forced expression of STAT3 increased the expression
levels of primary-miR-181b and mature miR-181b (Fig. 3h).
Collectively, these results suggest that STAT3 regulates
SFCs proliferation and increases colony formation of SFCs
by trans-activating miR-181b.
miR-181b regulates colony formation of SFCs via p-STAT3
We found that the expression level of miR-181b in Eca109
SFCs increased significantly compared with in the parental
cells (Fig. 4a). In addition, a miR-181b mimic led to a sig-
nificant mRNA increase in CD44 (Fig. 4b). Interestingly,
the CD24 expression level showed no obvious alterations
after transfection with the miR-181b mimic (Fig. 4b). More-
over, SFCs transfected with the miR-181b mimic increased
ABCB1, ABCG2, and MRP1 levels by more than two-fold
(Fig. 4c). Next, we tested the function of miR-181b in col-
ony formation in soft agar. The miR-181b mimic increased
the number of SFC colonies formed (Fig. 4d). In contrast,
the effect was reversed by miR-181b inhibitors (Fig. 4d).
To further explore whether miR-181b regulates prolif-
eration and colony formation, we performed in vitro
gain-of-function analyses by overexpression of miR-181b
with a lentiviral vector containing GFP in SFCs. We found
that ectopic expression of miR-181b significantly increased
colony size and the number of cells in the colonies
(Fig. 4e). In contrast, colony formation was remarkably
suppressed when miR-181b was silenced (Fig. 4e), suggest-
ing that miR-181b promotes the proliferation and colony
formation of SFCs.
To evaluate whether miR-181b regulates STAT3 ex-
pression, we conducted western blot analysis to detect
STAT3. The expression of p-STAT3 protein was signifi-
cantly increased after transfection with the miR-181b
mimic, whereas its expression was suppressed by miR-181b
inhibitors (Fig. 4f). Consistently, these results supported
those observations obtained using the p-STAT3 inhibitor
JSI-124 (Fig. 4f). Collectively, miR-181b positively regulates
p-STAT3 in SFCs.
Reciprocal activation between STAT3 and miR-181b is
critical for resistance of SFCs to apoptosis
Based on the above observations, we investigated the
biological significance of the reciprocal regulation mech-
anism between STAT3 and miR-181b. Consistent with
the results of previous studies [40, 44], inhibition of
STAT3 by JSI-124 or depletion of miR-181b with the in-
hibitor induced apoptosis compared with that measured
in NC cells (Fig. 5a). miR-181b mimic transfection sig-
nificantly protected SFCs from apoptosis induced by
interruption of STAT3 activation with JSI-124 (Fig. 5b).
Next, we analyzed the protein expression level of STAT3.
Increased expression levels of p-STAT3 induced by the
miR-181b mimic were reversed by the STAT3 inhibitor
JSI-124 (Fig. 5c, lane 2 and lane 3). However, the miR-
181b mimic increased the p-STAT3 expression level sup-
pressed by JSI-124 (Fig. 5c, lane 3 and lane 4). In addition,
forced STAT3 expression remarkably reversed apoptosis
induced by the inhibitor of miR-181b in SFCs (Fig. 5d). To
explore whether this effect was related to the miR-181b
expression level, miR-181b expression was analyzed. qPCR
analysis showed that forced STAT3 expression increased
miR-181b expression (Fig. 5e). Thus, mutual regulation
between STAT3 and miR-181b confers resistance to apop-
tosis in SFCs.
CYLD is a direct and functional target of miR-181b
According to previous studies [36, 46], the 3′-untrans-
lated region (UTR) of CYLD was identified as a target of
miR-181b. However, it was unknown whether the CYLD
3′-UTR is a target of miR-181b in SFCs. Our western
blot results demonstrated that forced STAT3 expression
decreased CYLD expression in Eca109 SFCs, whereas
siSTAT3 increaseded its expression (Fig. 6a). Consist-
ently, the CYLD expression changes were observed in
parental Eca109 cells (Fig. 6a). However, no appreciable
alterations in CYLD mRNA expression were observed in
SFCs regardless of whether STAT3 was present (Fig. 6b).
These results suggest that the reduction in CYLD is reg-
ulated at the post-transcriptional level and that the
CYLD 3′-UTR is a target of miR-181b in Eca109 SFCs.
Analysis using publicly available algorithms (TargetScan
and microRNA) predicted CYLD as a target of miR-181b
in Eca109 SFCs (Fig. 6c). Moreover, the 3′-UTR sequences
of CYLD were found to be highly conserved among dif-
ferent species and showed three possible binding sites
for miR-181b (Fig. 6c, D). To determine whether CYLD
is direct target of miR-181b, we engineered the 3′-UTR
fragments, in which wild-type and mutant binding sites
were inserted into the region immediately downstream of
the luciferase reporter gene (Fig. 6d). Luciferase reporter
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assays showed that miR-181b transfection significantly re-
pressed the luciferase activity of the CYLD 3′-UTR,
whereas mutations in the binding sites did not decreased
the luciferase activity (Fig. 6e). Moreover, qPCR analysis
showed that overexpression or inhibition of miR-181b
had no effect on the CYLD mRNA expression level
(Fig. 6f ). However, western blot analysis showed that
overexpression of miR-181b remarkably suppressed CYLD
expression in SFCs and that inhibition of miR-181b in-
creased CYLD expression in SFCs (Fig. 6g), indicating
that miR-181b regulates CYLD in SFCs at the post-
transcriptional level. Taken together, these results dem-
onstrate that miR-181b regulates CYLD expression by
directly targeting its 3′-UTR.
Fig. 4 miR-181b regulates colony formation of SFCs association with STAT3. a qPCR analysis of miR-181b in Eca109 parental cells and SFCs. U6
snRNA served as an internal control. b qPCR analysis of CD44 and CD24 in SFCs treated with miR-181b mimic or miR-181b inhibitor. c mRNA
expression levels of ABCB1, ABCG2, and MRP1 in SFCs treated with miR-181b mimic or miR-181b inhibitor. d Colony formation detection of SFCs
treated with miR-181b or miR-181b inhibitor in soft agar. Colonies formed were stained with 0.5 % crystal violet. Scale bar = 10 mm. e Colony
formation size detection of SFCs. SFCs were dissociated with trypsin and were transduced with miR-181b mimic or miR-181b inhibitor conjugated
with FAM. Scale bar = 50 μm. f Western blot analysis of p-STAT3 and STAT3 in SFCs treated with miR-181b mimic or with miR-181b inhibitor and
JSI-124. JSI-124 is a suppressor of p-STAT3. β-Actin and U6 snRNA served as internal controls. FAM, 5(6)-Carboxyfluorescein. SFCs, sphere formation
cells. Error bars represent mean ± SD
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According to previous studies, CYLD is a deubiquiti-
nating enzyme that negatively regulates NF-κB activity
[36, 47, 48]. To further assess the effect miR-181b
targeting CYLD, the activities of NF-κB and IL-6 were
measured. miR-181b transfection increased NF-κB
activity, while inhibition of miR-181b decreased this
activity (Fig. 6h). This alteration was also observed for
IL-6 activity, which is a target of NF-κB (Fig. 6i). NF-κB
and IL-6 activity were increased, which in turn increased
p-STAT3 level by western blot analysis. p-STAT3
expression level was decreased by IL-6 antibody treatment
(Additional file 1: Fig. S2). These results are consistent
with Fig. 4f. These results further suggest that CYLD is a
target of miR-181b.
Fig. 5 Reciprocal interaction between STAT3 and miR-181b conferred resistance to apoptosis. a Flow cytometry apoptosis analysis of SFCs treated
with p-STAT3 inhibitor JSI-124 and miR-181b inhibitor. b Apoptosis analysis of SFCs treated with JSI-124 and miR-181b mimic by flow cytometry.
SFCs were transiently transfected with miR-181b mimic and treated with 10 μM JSI-124. c Western blot analysis of SFCs treated with JSI-124 and
miR-181b mimic. β-Actin served as an internal control. d Flow cytometry to determine apoptosis of SFCs treated with miR-181b inhibitor and vector
pcDNA3.1 STAT3. SFCs were dissociated with trypsin, transiently transfected with vector pcDNA3.1 STAT3, and treated with 10 μM JSI-124 for 4 h.
e qPCR analysis of miR-181b in SFCs treated with miR-181b inhibitor and pcDNA3.1 STAT3 vector. U6 snRNA served as an internal control. Error bars
represent mean ± SD
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miR-181b regulates the SFC proliferation through CYLD
pathway
To further explore that miR-181b regulates the SFC prolif-
eration through CYLD pathway, soft agar experiment was
employed. The colonies efficiencies of SFCs was decreased
by siCYLD, which was reversed by miR-181b (Fig. 7a).
To address whether the above observations in SFC are
relevant to human cancer, we examine the relationship
Fig. 6 CYLD is identified as a direct and functional target of miR-181b. a Western blot analysis of CYLD in SFCs and Eca109 parental cells treated
with vector pcDNA3.1 STAT3 or siSTAT3. b CYLD expression level in SFCs quantified by qPCR. c Bioinformatics analysis conservation of CYLD
3′–UTR among different species and CYLD 3′-UTR is a target of miR-181b. d Diagram of CYLD 3′-UTR-containing reporter construct. Mutations
were generated at the three predicted miR-181b binding sites located in the CYLD 3′-UTR. e Luciferase reporter assays of wild-type and mutant reporter
plasmids cotransfected with miR-181b or NC into SFCs dissociated with trypsin. f qPCR analysis of CYLD in SFCs treated with miR-181b mimic or miR-181b
inhibitor. gWestern blot analysis of CYLD expression in SFCs treated with miR-181b mimic or miR-181b inhibitor. h NF-κB activity detection in SFCs treated
with miR-181b mimic or miR-181b inhibitor. i IL-6 activity detection in SFCs treated with miR-181b mimic or miR-181b inhibitor. β-Actin was
used as an internal control. Error bars represent mean ± SD
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between STAT3 and miR-181b expression levels in hu-
man ESCC specimens. We collected clinical samples of
ESCC (Additional file 1: Table S1) and enriched the
SFCs using serum-free culture. There is a positive cor-
relation between STAT3 and miR-181b expression levels
in the cancer specimens (r = 0.683) (Fig. 7b). In addition,
we found an inverse correlation between miR-181b and
CYLD (r = -0.867) (Fig. 7c). These data further support
the notion that there is a positive and mutual regulation
between STAT3 and miR-181b and that CYLD is a tar-
get of miR-181b. Collectively, these studies demonstrate
that miR-181b regulates the proliferation of SFCs through
CYLD pathway.
Discussion
The CSC hypothesis suggests that current therapies fail
to prevent cancer relapse and metastasis because of the
existence of a small population of tumor stem cells [49].
The tumorsphere, side population cells, and drug-resistant
cells have cancer stem cell-likes properties [21]. Side
population cell sorting technology is widely used to
identify cancer stem cell-like cells in cancer, and the ABC
transporter family member ABCG2 is an unfavorable
prognostic factor in ESCC [50–52]. In addition, stemness
factors including Nanog, Sox2, Oct4, and Bmi1 are highly
expressed in cancer cells and have cancer stem cell prop-
erties [53–57]. Previous studies demonstrated that the
tumor sphere can be applied to isolate a CSC population
from cancer cells [19–21, 37]. According to these studies,
tumor sphere-forming cells have the capacity for prolifera-
tion and self-renewal and possess high tumorigenicity.
In this present study, we isolated cancer stem cells
using suspension culture methods and enriched high
levels of stemness factors from SFCs. Furthermore,
qPCR analysis showed that mesenchymal trait factors in-
cluding ZEB1, ZEB2, Slug, Snail, and N-cadherin were
expressed at higher levels in Eca109 cells than in the
parental cells, suggesting that these SFCs transition to
mesenchymal traits, which is linked to the epithelial-to-
mesenchymal transition. In addition, stemness factors,
such as Nanog, Oct4, Sox2, and Bmi1, showed higher
expression in SFCs in Eca109 cells but not in Eca9706
cells compared to the parental cells. These results dem-
onstrate that Eca109 cells can be enriched for esophageal
CSC more easily than Eca9706 cells. Other studies re-
vealed CD44 expression in CSCs, including in ESCC
Fig. 7 miR-181b regulates the proliferation of SFCs through CYLD. a Soft agar experiment was employed analyze the relationship between miR-
181b and CYLD. Colonies were counted following 0.5 % crystal violet staining. The experiments were performed three times independently. Scale
bar = 10 mm. b STAT3 and miR-181b expression levels in esophageal cancer, with each data point representing an individual sample. c miR-181b
and CYLD expression levels in esophageal cancer, with each data point representing an individual sample. Spearman analysis were employed to
analyzed the relationship between STAT3 and miR-181b, miR-181b and CYLD
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tumor-initiating cells [38, 58, 59]. Our results agree
with these previous results. In addition, SFCs expressed
CD44 + CD24-, and in vivo studies demonstrated that
SFCs possessed stronger tumorigenicity than the paren-
tal cells.
We found that mutual regulation between STAT3 and
miR-181b is essential for regulating the proliferation and
resistance of SFCs. First, STAT3, a constitutively expressed
factor, is critical in several types of cancers [41, 43, 60, 61].
In our study, p-STAT3 showed increased expression in
SFCs compared to that in parental cells and STAT3 in-
creased the number of SFC colonies. Moreover, STAT3
could bind to the promoter of miR-181b, suggesting that
STAT3 is a direct transcriptional activator of miR-181b.
This is in accordance with the results of Iliopoulos et al.
[36]. Additionally, STAT3 increased miR-181b expression
level in our study. Second, miR-181b increased the number
of colonies of SFCs. Western blot analysis showed that
miR-181b increased p-STAT3 expression. Third, both
STAT3 and miR-181b inhibition sensitized SFCs to apop-
tosis. These observations indicate that reciprocal regulation
between STAT3 and miR-181b is critical for regulating the
proliferation of SFCs.
miRNAs have emerged as important regulators of gene
expression at the post-transcriptional level and regulate
physiological processes and tumor progression [62]. In
our study, potential targets of miR-181b were analyzed
using different algorithms. Our study to determine the
biological role of miR-181b in SFCs identified CYLD as
a downstream target. Luciferase reporter assays revealed
that CYLD is a target of miR-181b. In addition, according
to previous studies, CYLD negatively regulates NF-κB ac-
tivity [47, 48]. Our results demonstrated that exogenous
miR-181b increased NF-κB activity. In this study, the miR-
181b mimic also increased IL-6 expression level.
Conclusions
In this study we enriched esophageal cancer stem-like cells
in the Eca109 cell line and determined their tumorigenicity.
Mutual regulation between STAT3 and miR-181b is essen-
tial for SFCs to regulate proliferation and the resistance to
apoptosis. Furthermore, CYLD is a direct and functional
target of miR-181b. This study provides insight into the
mechanisms underlying the reciprocal regulation between
STAT3 and miR-181b to regulate the proliferation of
esophageal cancer cells with cancer stem-like cells proper-
ties via the CYLD pathway. These findings maybe is helpful
for targeting esophageal cancer stem-like cells and provid-
ing therapeutic approach for esophageal cancer treatments.
Methods
Esophageal cancer cell suspension culture conditions
Eca109 and Eca9706 cells were cultured in serum-free
DMEM/F12 medium (SFDM) (Gibco, Grand Island, NY,
USA) supplemented with B27 (Gibco), 20 ng/mL basic
fibroblast growth factor (bFGF) (Pepro Tech, Inc., Rocky
Hill, NJ, USA), 20 ng/mL epidermal growth factor (EGF)
(Pepro Tech, Inc.), and 1 % penicillin and streptomycin
using ultra-low attachment plates (Corning, Inc., Corning,
NY, USA). Spheres were dissociated using trypsin every
5 days. Human esophageal cancer tissue were collected in
Sun Yet-Sen University cancer center. Written informed
consent was obtained from all esophageal cancer patients
before the study. The use of the clinical specimens for
research purposes was approved by the Jinan University
Ethics Committee.
RNA isolation and qPCR analysis
Total RNA was extracted using Trizol reagent (Tiangen,
Beijing, China) and were reverse-transcribed into cDNA
by using PrimerScript Master mix (TaKaRa Biotechnol-
ogy, China) according to the manufacturer’s protocol.
The PCR primers for miR-181b and U6 were purchased
from RiBoBio (Guangzhou, China). The following PCR
conditions were used on the Light Cycler: 95 °C for 5 s,
60 °C for 5 s, followed by 42 cycles of 95 °C for 15 s and
60 °C for 1 min in a 10 μL reaction volume. The expres-
sion of U6 or β-actin was used as an internal control.
All experiments were conducted in triplicate. Real-time
quantitative PCR was performed using the Bio-Rad sys-
tem (Hercules, CA, USA) and TaqMan system (Applied
Biosystems, Foster City, CA, USA).
Western blot analysis
Proteins were harvested in cold RIPA buffer. Samples
were collected and measured for protein concentration
(BCA protein A assay, Byotime, Haimen, China). Pro-
teins were separated by SDS–PAGE and transferred onto
polyvinylidene fluoride membranes (Millipore, Billerica,
MA, USA). Membranes were blocked in TBST-0.1 %
(0.1 % Tween-20 in Tris-base buffer) skim milk and blot-
ted with primary antibodies including STAT3, p-STAT3,
CYLD, and β-actin (#9139, #9145, #8462, #4970,respect-
ively, all from Cell Signaling Technology, Danvers, MA,
USA) at 4 °C overnight. IL-6 neutralising antibody
(#ab6672) was purchased from abcam (USA). Next day
the membranes were washed three times TBST-0.1 %
buffer. Then the membranes were then incubated with
secondary antibodies (Millipore). The signals on the
membranes were revealed with ECL reagent (Thermo
Scientific, Waltham, MA, USA).
Flow cytometry analysis
For flow cytometry analysis, 1 × 106 cells were incubated
with anti-CD44 (eBioscience, San Diego, CA, USA) PE-
conjugated antibody, and anti-CD24 (BD Biosciences,
Franklin Lakes, NJ, USA) FITC-conjugated antibody for
30 min, washed three times, and resuspended in PBS.
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Data were analyzed using Flow Jo software (Tree Star,
Ashland, OR, USA). CD44 and CD24 double-negative and
single-positive staining controls were used for compensa-
tion. Cell staining was visualized using a Nikon inverted
microscope (Tokyo, Japan).
Sphere formation assay
According to previous studies [20, 63], sphere formation
assays were performed using 96-well ultra-low attach-
ment cell culture plates. Eca109 cells were mixed with
serum-free DMEM/F12 sphere culture media containing
B27, EGF, and bFGF and then seeded into each well.
Plates were incubated for 2 weeks until spheres formed;
wells containing spheroid cells were counted.
Colony formation assay
According to previous studies [20, 63], colony formation
assays were performed using 6-well cell culture plates
coated with 0.5 mL bottom soft agar mixture (DMEM/
F12, 20 % FBS, 0.6 % soft agar). After the bottom layer
had solidified, the cells were mixed with top agar
(DMEM/F12, 20 % FBS, 0.3 % soft agar), and seeded into
each well (3 wells for each concentration). Plates were
incubated for 2 weeks until colonies were large enough
to be visualized. Colonies were stained with 0.5 % crystal
violet for 30 min and counted.
miRNA mimic and transfection
The miR-181b mimic, miR-181b inhibitor, and NC cells
were purchased from RIBOBIO (Guangzhou, China). The
sequence containing the pre-miR-181b was cloned into the
pGCSIL-GFP lentiviral. The miR-181b mimic and siRNA
were used with Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s proto-
col. The siRNA against CYLD was refered to Yang’s study
[64] and was purchased from Genechem (Shanghai, China).
Targeted cells were infected using 1 × 108 lentivirus trans-
ducing unit with 8 μg/mL polybreneaccording to the manu-
facturer's instructions.
Luciferase reporter assay
The plasmid pcDNA3.1-STAT3-wt UTR was constructed
by inserting the STAT3 cDNA into the pcDNA3.1 vector
(Invitrogen) at the Xhol and Xbal sites. To construct a lu-
ciferase reporter vector, the wild-type 3′-UTR of CYLD,
containing three putative binding sites for miR-181b, was
PCR-amplified using genomic cDNA from SFCs as tem-
plates. The corresponding mutant constructs were created
by mutating the seed regions of the miR-181b-binding
sites. Both wild-type and mutant 3′-UTRs were cloned
downstream of the luciferase gene in the luciferase vector.
For luciferase reporter assays, SFCs were transiently trans-
fected with the reporter plasmid and miRNA using Lipo-
fectamine 2000. After 48 h, the cells were harvested and
lysed, and luciferase activity was measured using the Lucif-
erase Reporter Assay System (Promega, Madison, WI,
USA). Renilla luciferase was used for normalization. For
each plasmid construct, the transfection experiments were
performed in triplicate.
Animals and xenograft model
The handling of mice and experimental protocol were
approved by the Experiment Animal Care Committee of
Jinan University (Guangzhou, China). 5-week-old male
Balb/c mice were purchased from the Animal center of
Guangdong Province (Guangzhou, China). Cells from
Eca109 cancer parental cell lines or from the SFCs were
trypsinized, washed twice, and counted. Next, 5 × 105
cells were resuspended in 100 μL PBS, mixed an equal
volume of Matrigel (BD Biosciences) and injected sub-
cutaneously into the neck area of each mouse. Mice
were sacrificed after 4 weeks and the tumors were har-
vested and measured. Tumor weight was measured for
statistical analysis. Xenografts were divided into two
parts and one was snap-frozen in liquid nitrogen for
RNA isolation while the other was used for western blot
analysis. Animal studies were approved by the Jinan Uni-
versity Ethics Committee.
Statistical analysis
The SPSS19.0 program (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Experimental data are pre-
sented as the means ± SD for at least three independent
experiments. Student’s t-tests were used for two-group
comparisons. Differences between groups were assessed
by one-way analysis of variance when more than two
groups were compared. Spearman analysis were employed
to analyzed the relationship between STAT3 and miR-
181b, miR-181b and CYLD. Differences were considered
statistically significant at *P < 0.05 and **P < 0.01.
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